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ABSTRACT 1 
Background 2 
Rotational atherectomy (RA) is an important interventional tool for heavily calcified 3 
coronary lesions. We compared the early clinical outcomes in patients undergoing RA using 4 
radial or femoral access. 5 
 6 
Methods and Results 7 
We identified all patients in England and Wales who underwent RA between January 1, 2005 8 
and March 31, 2014. 8622 RA cases (3069 radial and 5553 femoral) were included in the 9 
analysis. The study primary outcome was 30-day mortality. Propensity scores (PS) were 10 
calculated to determine the factors associated with treatment assignment to radial or femoral 11 
access. Multivariable logistic regression analysis, using the calculated PS, was performed. 12 
30-day mortality was 2.2% in the radial and 2.3% in the femoral group (p = 0.76). Radial 13 
access was associated with equivalent 30-day mortality (adjusted odds ratio [OR], 1.06; 95% 14 
confidence interval [CI], 0.77 to 1.46; p = 0.71), procedural success (OR, 1.04; 95% CI, 0.84 15 
to 1.29; p = 0.73), major adverse cardiac and cerebrovascular events (OR, 1.05; 95% CI, 0.80 16 
to 1.38; p = 0.72) and net adverse clinical events (OR, 0.90; 95% CI 0.71 to 1.15; p = 0.41), 17 
but lower rates of in-hospital major bleeding (OR, 0.62; 95% CI, 0.40 to 0.98; p = 0.04) and 18 
major access site complications (OR, 0.05; 95% CI, 0.01 to 0.38; p = 0.004), compared with 19 
femoral access. 20 
 21 
Conclusions 22 
In this large real-world study of patients undergoing RA, radial access was associated with 23 
equivalent 30-day mortality and procedural success, but reduced major bleeding and access 24 
site complications, compared with femoral access.   25 
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 3 
INTRODUCTION 1 
Rotational atherectomy (RA) is an important option for the percutaneous treatment of heavily 2 
calcified and undilatable coronary lesions (1,2). Historically, femoral artery access was the 3 
preferred approach for RA, due to a perceived need for large calibre guiding catheters to 4 
accommodate atherectomy burrs with the primary aim of calcium debulking. RA has since 5 
evolved into a plaque modification technique, requiring smaller burr sizes, with the aim of 6 
facilitating subsequent balloon dilation and implantation of drug-eluting stents (DES). This 7 
evolution presents the opportunity to routinely perform RA using radial artery access (3).  8 
In a recent meta-analysis of 24 randomized trials in stable and unstable coronary syndromes, 9 
radial access for percutaneous coronary intervention (PCI) was found to reduce overall 10 
mortality and improve patient safety, compared with femoral access. There were reductions 11 
in major vascular complications and bleeding across the entire spectrum of patients with 12 
coronary artery disease (4). Radial access leads to earlier patient ambulation compared with 13 
femoral access (5) and is preferred by patients (6). However, there are no large-scale studies 14 
to support radial access as the preferred approach for RA in contemporary clinical practice. 15 
Reliable comparative data for procedural success and the risk of adverse events after RA, 16 
associated with arterial access, site are lacking. This paucity of evidence is important because 17 
radial access is increasingly being used worldwide and there has been a resurgence of interest 18 
in RA, due to the anatomical complexity of the ageing population and the effectiveness of 19 
DES to negate the limitations of RA. Patients who undergo RA have a high risk of recurrent 20 
ischemia and bleeding (7) and would benefit from strategies to improve periprocedural 21 
safety, but not at the cost of reduced efficacy. Therefore, in a large population of consecutive 22 
patients undergoing RA in the United Kingdom (UK), we compared the procedural and 30-23 
day outcomes using radial access versus femoral access. 24 
 25 
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
 4 
METHODS 1 
Data collection 2 
The British Cardiovascular Intervention Society (BCIS) collects data related to all PCI 3 
procedures performed in the UK. The National Institute of Cardiovascular Outcomes 4 
Research (NICOR) manages this database. The BCIS-NICOR database documents more than 5 
100 clinical, procedural and outcome variables. These include demographic data, baseline 6 
clinical parameters, angiographic findings and procedural details. In-hospital death, major 7 
adverse cardiac and cerebrovascular events (MACCE), major bleeding and access site 8 
complications are recorded. Data is collected according to a standard set of definitions and 9 
used for national audit and quality purposes, including public reporting of results. Any 10 
research department in the UK can apply to receive anonymised data from BCIS-NICOR for 11 
the purposes of research. Mortality tracking was provided by the Medical Research 12 
Information Service, using unique patient identifiers for all persons registered with the 13 
National Health Service in England and Wales. Mortality tracking was unavailable for 14 
patients treated in Scotland or Northern Ireland, therefore all procedures from these countries 15 
were not included. 16 
 17 
Study population 18 
All RA procedures in England or Wales between January 1, 2005 and March 31, 2014 were 19 
included. Patients who underwent RA via the right or left radial artery, or the right or left 20 
femoral artery, were included in the radial and femoral groups, respectively. Patients who had 21 
both radial and femoral arterial access sites used during the same procedure were excluded. 22 
Further exclusions were made for missing access site or 30-day mortality data. 23 
 24 
Clinical outcomes 25 
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 5 
The primary outcome of this study was 30-day mortality. The secondary outcomes were 1 
procedural success, in-hospital major bleeding, in-hospital major access site complications, 2 
in-hospital MACCE and net adverse clinical events (NACE). Procedural success was 3 
recorded by the local operator. Major bleeding was defined as gastrointestinal, intracranial or 4 
retroperitoneal bleeding, pericardial bleeding causing tamponade, or any bleeding requiring 5 
blood or platelet transfusion or resulting in surgery. Major access site complications were 6 
defined as false aneurysm, retroperitoneal bleeding, major arterial dissection, access site 7 
bleeding requiring blood or platelet transfusion, resulting in surgery or causing delayed 8 
discharge. MACCE was defined as a composite of 30-day mortality, in-hospital myocardial 9 
infarction, in-hospital target vessel revascularisation (TVR) or in-hospital cerebrovascular 10 
event (stroke or transient ischemic attack). NACE was a composite of MACCE or in-hospital 11 
major bleeding. Complete revascularisation was defined as zero vessels with obstructive 12 
stenosis post-PCI (left main stem ≥ 50%, or left anterior descending, circumflex or right 13 
coronary artery ≥ 75%), excluding cases with previous, unknown or missing coronary artery 14 
bypass grafting (CABG) status and residual obstructive stenosis, as BCIS does not record 15 
data for bypass graft patency. 16 
 17 
Statistical Analysis 18 
Data analysis was performed using Stata V14.1 (College Station, Texas). Baseline data were 19 
compared for all eligible RA cases by radial and femoral access site. Missing data were dealt 20 
with by imputation through chained equations (ICE) using the “ice” module in Stata. The 21 
degree of missing data is provided in the Supplementary Table. We used the FMI (fraction of 22 
missing data) to determine the number of imputed data sets. Baseline data were compared 23 
using χ2 statistic for categorical variables and Kruskal-Wallis tests for continuous data. We 24 
estimated odds ratios (ORs) of study outcomes associated with access site using logistic 25 
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 6 
regression models. The association between access site and outcome was first assessed with 1 
univariable logistic regression.  2 
To allow appropriate multivariable adjustment, and to avoid the issue of overfitting, a two-3 
step process employing propensity scores (PS) was used. First, we calculated the PS for each 4 
case, defining the dependent outcome as access site (radial or femoral). The PS was 5 
calculated, based on predefined clinically important covariables, available within the BCIS-6 
NICOR database. The following variables were included in the PS model: age, sex, diabetes, 7 
hypertension, peripheral arterial disease, clinical presentation (stable or acute coronary 8 
syndrome [ACS]), renal disease, hypercholesterolemia, largest balloon or stent diameter, 9 
stent length, number of vessels treated, artery treated, mechanical support, family history, 10 
previous CABG, use of glycoprotein inhibitor, deprivation quintile, cardiogenic shock, 11 
previous stroke or transient ischemic attack, use of DES, impaired left ventricular (LV) 12 
function, recent fibrinolysis, heart block requiring pacing and year of procedure. The second 13 
step was to use the calculated PS as a covariable adjustment when assessing the association 14 
between radial (vs. femoral) access and the study outcomes. Both univariable and 15 
multivariable (PS-adjusted) logistic regression analyses are reported. 16 
 17 
RESULTS 18 
Study population 19 
The flow of procedures in the study is shown in Figure 1.  A total of 729 268 PCI procedures 20 
were recorded by BCIS-NICOR in England and Wales between January 1, 2005 and March 21 
31, 2014, of which 9712 (1.3%) involved RA. 8622 RA procedures had utilized a single 22 
arterial access route (radial or femoral only) and were included in the analysis. There were 23 
3069 RA procedures in the radial group and 5553 in the femoral group. There was a 24 
progressive increase in the use of radial access for RA throughout the study period (Figure 2). 25 
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 7 
Patients in the radial group were more likely to be male and treated for an ACS, and had a 1 
lower incidence of previous CABG, renal disease, impaired LV function, mechanical support 2 
and temporary pacing (Table 1). A higher rate of DES implantation was present in the radial 3 
group, reflecting the temporal shift in the use of radial access and DES use. Use of 4 
glycoprotein inhibitors and recent fibrinolysis were similar in both groups. The PS was 5 
calculated and the c-statistic was 0.68, indicating moderate to good discrimination. The 6 
Hosmer-Lemeshow test was non-significant (p = 0.32). 7 
 8 
Relationship between access site and 30-day mortality 9 
Crude 30-day mortality was available for all patients and was 2.25% (194/8622) in the 10 
overall RA population, 2.18% (67/3069) in patients treated using radial access and 2.29% 11 
(127/5553) in patients treated using femoral access (radial [vs. femoral] OR, 0.95; 95% 12 
confidence interval [CI], 0.71 to 1.29; p = 0.76) (Table 2 and 3). PS-adjusted logistic 13 
regression analysis was performed, accounting for differences in baseline clinical and 14 
procedural characteristics, and demonstrated no difference in 30-day mortality between radial 15 
and femoral groups (adjusted OR, 1.06; 95% CI, 0.77 to 1.46; p = 0.71) (Table 3). There was 16 
no difference in the time trend analysis of 30-day mortality, based on year of procedure (test 17 
of homogeneity [equal odds], p = 0.36). 18 
 19 
Relationship between access site and secondary outcomes 20 
The crude rates of all prespecified study outcomes associated with access site are shown in 21 
Table 2. Univariable and PS-adjusted ORs using radial access as a predictor of study 22 
outcomes are shown in Table 3. Procedural success was equivalent in radial and femoral 23 
groups (95.2% vs. 94.9%; p = 0.56; adjusted OR, 1.04; 95% CI, 0.84 to 1.29; p = 0.73). 24 
Radial access was associated with a lower incidence of in-hospital major bleeding, compared 25 
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 8 
with femoral access (1.0% vs. 1.8%; p = 0.004). Using PS-adjusted logistic regression 1 
analysis, radial access was independently associated with a lower incidence of in-hospital 2 
major bleeding (adjusted OR, 0.62; 95% CI, 0.40 to 0.98; p = 0.04). Radial access was 3 
associated with a lower incidence of major access site complications, compared with femoral 4 
access (0.04% vs. 1.3%; p < 0.001); after PS-adjustment, radial access was independently 5 
associated with a reduction in major access site complications (adjusted OR, 0.05; 95% CI, 6 
0.01 to 0.38; p = 0.004).  7 
The incidence of MACCE was similar in radial and femoral groups (3.2% vs. 3.5%; p = 0.37; 8 
adjusted OR, 1.05; 95% CI, 0.80 to 1.38; p = 0.72). There was a lower incidence of NACE in 9 
the radial group (3.7% vs. 4.9%; p = 0.01); however, after PS-adjustment, we found no 10 
difference for this outcome (adjusted OR, 0.90; 95% CI, 0.71 to 1.15; p = 0.41). The 11 
incidence of 30-day mortality, in-hospital myocardial infarction or cerebrovascular event 12 
(2.9% vs. 3.4%; p = 0.22; adjusted OR, 0.99; 95% CI, 0.75 to 1.32; p = 0.97) and in-hospital 13 
TVR (0.3% vs. 0.2%; p = 0.28; adjusted OR, 1.58; 95% CI, 0.63 to 3.94; p = 0.32) were not 14 
different between radial and femoral groups, respectively. The rate of complete 15 
revascularization was lower in patients treated using radial access (63.7% vs. 66.8%; p = 16 
0.02); however, after PS-adjustment, radial access was not an independent predictor of 17 
complete revascularization (adjusted OR 0.92, 95% CI, 0.82 to 1.04; p = 0.19).  18 
 19 
DISCUSSION 20 
The BCIS-NICOR database effectively includes the totality of UK experience and outcomes 21 
related to the use of RA during the past decade.  This observational study is the largest real-22 
world comparison of patients undergoing RA via the radial or femoral arterial access route. 23 
We found no difference in 30-day mortality between radial and femoral groups. The absence 24 
of early mortality benefit associated with radial access in this study may reflect the 25 
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 9 
predominantly stable population treated (approximately two-thirds of procedures were for 1 
stable angina) and the very low incidence of RA performed in the primary or rescue PCI 2 
population (1.3% of cases in this study), both of which represent patient groups in whom the 3 
greatest mortality benefit with radial access has been demonstrated. However, radial access 4 
was associated with equivalent procedural success and a significantly lower incidence of in-5 
hospital major bleeding and major access site complications, suggesting radial access was the 6 
safer approach for RA.  Importantly, no drawbacks of radial access were identified, despite 7 
the historical perceived advantages of femoral access. 8 
Whilst no differences in survival were identified in our analysis, avoidance of vascular 9 
complications and bleeding is a major safety principle in modern PCI practice. In other 10 
studies, access site bleeding has been independently associated with an increase in mortality 11 
in patients undergoing PCI (8,9). Periprocedural major bleeding increases the risk of early 12 
and late mortality (10, 11), and the adverse effect n survival is more pronounced in women, 13 
who have a higher risk of major bleeding than men (12). Preprocedural risk stratification for 14 
bleeding may prompt implementation of bleeding avoidance strategies (including radial 15 
access) that can reduce the risk of major bleeding associated with PCI (13).  16 
RA necessitates additional technical and training considerations compared to standard PCI, 17 
perhaps reflected in the relatively cautious adoption of radial access for this procedure in the 18 
UK. However, there is now widespread understanding that the technical challenges and 19 
procedure-related complications related to the historical calcium debulking technique can be 20 
overcome in the great majority using a contemporary smaller (and usually single) burr 21 
approach (3). A 6 French guiding catheter can easily accommodate a 1.25 mm or 1.5 mm 22 
atherectomy burr and, in some cases, a 1.75 mm burr, depending on the internal catheter 23 
dimensions stated by the manufacturer and experience of the operator. Contemporary RA 24 
using burrs within this range (providing a burr-to-artery ratio of 0.5-0.6) will, in most cases, 25 
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 10 
fulfil the main objective of plaque modification, by disrupting the continuity of concentric 1 
atherosclerotic calcium rings. If more extensive RA is required, 1.75 mm and 2.00 burrs can 2 
be accommodated using a 7 or 7.5 French guiding catheter, which are compatible with most 3 
radial arteries, when inserted through a thin-walled hydrophilic sheath (14) or using a 4 
sheathless approach (15). Radial access enables more patients with severe peripheral arterial 5 
disease or high bleeding risk, such as the elderly and patients presenting with ACS, to 6 
undergo RA safely and effectively. Given the safety and potential for routine early 7 
ambulation after radial procedures, day case elective RA may be feasible for some patients.  8 
 9 
Advantages 10 
Using the BCIS-NICOR dataset, we have been able to study 8622 complex PCI cases 11 
involving RA during the past decade. It is highly unlikely that this number of RA procedures 12 
could be studied in a prospective randomized controlled manner. Thus, in the present PCI era, 13 
the current RA study provides a unique pportunity to study the effects of important 14 
procedural factors in this complex and increasingly common lesion subset. Mortality tracking 15 
was complete for all patients, and this provided a robust and unbiased primary end-point. 16 
Although observational in nature, the positive findings of this study are consistent with the 17 
weight of evidence supporting radial access for PCI in patients with less complex lesion 18 
types. 19 
 20 
Limitations 21 
Our study has some limitations. Due to the retrospective observational nature of the study, 22 
differences may exist between groups which may affect the success and safety of each 23 
approach if examined in a prospective randomized manner. Hence, we cannot prove causality 24 
or exclude the possibility of residual confounding.  It was not possible to assess whether both 25 
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
 11 
radial and femoral access were equally feasible for each individual case. In-hospital 1 
complications were recorded by individual institutions and may have been subject to under-2 
reporting. The radial group differed from the femoral group with respect to several baseline 3 
variables, however we performed multivariable logistic regression using PS, to adjust for 4 
potential confounding.  5 
Certain data are unavailable in the BCIS-NICOR national dataset, and cannot be added 6 
retrospectively. Anatomical features, such as degree of calcification or tortuosity, were not 7 
recorded and, if lesion complexity had been significantly different between groups, this may 8 
have influenced the relative procedural success and incidence of complications. Patient 9 
radiation exposure and procedure time were not known; however, we have previously 10 
reported no access site-dependent difference in these parameters for rotational atherectomy 11 
(16). Data for arterial sheath, guiding catheter or burr size were not recorded, although it is 12 
likely that these were smaller in the radial group (16). Smaller calibre devices may contribute 13 
to improved safety with radial access, but without reduced procedural success, when using a 14 
contemporary RA technique.  15 
Limitations in collected data fields and missing data are inherent in studies derived from 16 
large-scale national registries. However, the large number of cases available for comparison 17 
more than mitigates these shortcomings and provides an invaluable insight into real-world 18 
practice.  19 
 20 
CONCLUSION 21 
We have demonstrated in a large all-comer UK population of 8622 patients undergoing RA, 22 
that radial access was associated with equivalent 30-day mortality, procedural success and 23 
MACCE, compared with femoral access. Radial access was associated with a lower risk of 24 
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 12 
in-hospital major bleeding and major access site complications, thus supporting radial access 1 
as the default contemporary approach for most patients requiring RA.  2 
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  Table 1. Baseline clinical and procedural characteristics. 1 
Variable Radial (n = 3069) Femoral (n = 5553) p Value 
Age, yrs. 72.5 ± 0.17 73.0 ± 0.12 0.006 
Male 2299/3062 (75.1) 3893/5541 (70.3) < 0.001 
ACS 1233/3069 (40.2) 1896/5553 (34.1) < 0.001 
Diabetes 911/2994 (30.4) 1604/5309 (30.2) 0.84 
Smoking history 1851/2843 (65.1) 2963/4840 (61.2) 0.001 
Hypercholesterolaemia 2010/2932 (68.6) 3698/5227 (70.8) 0.04 
Hypertension 2129/2937 (72.5) 3917/5227 (74.9) 0.02 
Previous MI 1072/2854 (37.6) 2125/5019 (42.3) < 0.001 
Previous CABG 349/3016 (11.6) 964/5407 (17.8) < 0.001 
Impaired LV function (EF <50%) 730/2138 (34.1) 1239/3326 (37.3) 0.02 
Cardiogenic shock 19/2849 (0.7) 57/5151 (1.1) 0.05 
Peripheral arterial disease 369/2932 (12.6) 603/5221 (11.6) 0.17 
Previous stroke or TIA 245/2931 (8.4) 373/5223 (7.1) 0.05 
Renal disease 139/2923 (4.8) 418/5230 (8.0) < 0.001 
No. of vessels attempted 1.37 ± 0.01 1.34 ± 0.01 0.02 
Vessel attempted -    
     Left main stem 387/3055 (12.7) 914/5522 (16.6) < 0.001 
     Left anterior descending artery 1752/3055 (57.3) 2879/5522 (52.1) < 0.001 
     Circumflex artery 645/3055 (21.1) 1118/5522 (20.2) 0.34 
     Right coronary artery 1021/3055 (33.4) 1984/5522 (35.9) 0.02 
     Bypass graft 27/3055 (0.9) 76/5522 (1.4) 0.05 
No. of lesions attempted 1.62 ± 0.02 1.61 ± 0.01 0.68 
Drug-eluting stent used 2677/3046 (87.9) 4533/5471 (82.9) < 0.001 
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Glycoprotein inhibitor used 378/2751 (13.7) 751/5058 (14.9) 0.18 
Recent fibrinolysis 30/1268 (2.4) 40/2182 (1.8) 0.29 
Mechanical support 46/2825 (1.6) 174/5209 (3.3) < 0.001 
Temporary pacing 12/2819 (0.4) 42/5169 (0.8) 0.04 
 1 
Values are mean ± SD or n/denominator (%). ACS acute coronary syndrome, MI myocardial 2 
infarction, CABG coronary artery bypass grafting, LV left ventricular, EF ejection fraction, 3 
TIA transient ischemic attack.  4 
 5 
  6 
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Table 2. Access site and crude rate of study outcomes.  1 
Outcome Radial (n=3069) Femoral (n=5553) p Value 
30-day mortality 67/3069 (2.2) 127/5553 (2.3) 0.76 
Procedural success 2906/3052 (95.2) 5173/5449 (94.9) 0.56 
In-hospital major bleeding 29/2969 (1.0) 96/5402 (1.8) 0.004 
Major access site complication 1/2782 (0.04) 66/5184 (1.3) < 0.001 
MACCE 94/2969 (3.2) 191/5401 (3.5) 0.37 
NACE 111/2969 (3.7) 265/5401 (4.9) 0.01 
 2 
Values are n/denominator (%). MACCE major adverse cardiac and cerebrovascular events. 3 
NACE net adverse clinical events. 4 
  5 
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Table 3. Univariable and multivariable analysis using radial access (vs. femoral) as a 1 
predictor of study outcomes.  2 
Outcome Univariable OR 
(95% CI) 
p Value Multivariable OR 
(95% CI) 
p Value 
30-day mortality 0.95 (0.71-1.29) 0.76 1.06 (0.77-1.46) 0.71 
Procedural success 1.05 (0.86-1.29) 0.62 1.04 (0.84-1.29) 0.73 
In-hospital major bleeding 0.54 (0.36-0.82) 0.004 0.62 (0.40-0.98) 0.039 
Major access site complication  0.05 (0.01-0.30) 0.001 0.05 (0.01-0.38) 0.004 
MACCE 0.89 (0.69-1.14) 0.36 1.05 (0.80-1.38) 0.72 
NACE 0.78 (0.63-0.97) 0.03 0.90 (0.71-1.15) 0.41 
 3 
MACCE major adverse cardiac and cerebrovascular events. NACE net adverse clinical 4 
events. 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
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Supplementary Table. Baseline characteristics and extent of missing data. 1 
 2 
Variable 
 
Radial (n = 3069) Femoral (n = 5553) 
   
Age, yrs 72.5 ± 0.17 73.0 ± 0.12 
Missing 1 2 
   
Male 2299/3062 (75.1) 3893/5541 (70.3) 
Missing 7 12 
   
ACS 1233/3069 (40.2) 1896/5553 (34.1) 
Missing 0 0 
   
Diabetes 911/2994 (30.4) 1604/5309 (30.2) 
Missing 75 244 
   
Smoking history 1851/2843 (65.1) 2963/4840 (61.2) 
Missing 226 713 
   
Hypercholesterolaemia 2010/2932 (68.6) 3698/5227 (70.8) 
Missing 137 326 
   
Hypertension 2129/2937 (72.5) 3917/5227 (74.9) 
Missing 132 326 
   
Previous MI 1072/2854 (37.6) 2125/5019 (42.3) 
Missing 215 524 
   
Previous CABG 349/3016 (11.6) 964/5407 (17.8) 
Missing 53 146 
   
Impaired LV function (EF <50%) 730/2138 (34.1) 1239/3326 (37.3) 
Missing 931 2227 
   
Cardiogenic shock 19/2849 (0.7) 57/5151 (1.1) 
Missing 220 402 
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Peripheral arterial disease 369/2932 (12.6) 603/5221 (11.6) 
Missing 137 332 
   
Previous stroke or TIA 245/2931 (8.4) 373/5223 (7.1) 
Missing 138 330 
   
Renal disease 139/2923 (4.8) 418/5230 (8.0) 
Missing 146 323 
   
No. of vessels attempted 1.37 ± 0.01 1.34 ± 0.01 
Missing 20 37 
   
Vessels attempted -   
   
Left main stem 387/3055 (12.7) 914/5522 (16.6) 
Missing 14 31 
   
Left anterior descending artery 1752/3055 (57.3) 2879/5522 (52.1) 
Missing 14 31 
   
Circumflex artery 645/3055 (21.1) 1118/5522 (20.2) 
Missing 14 31 
   
Right coronary artery 1021/3055 (33.4) 1984/5522 (35.9) 
Missing 14 31 
   
Bypass graft 27/3055 (0.9) 76/5522 (1.4) 
Missing 14 31 
   
No. of lesio s attempted 1.62 ± 0.02 1.61 ± 0.01 
Missing 20 37 
   
Drug-eluting stent used 2677/3046 (87.9) 4533/5471 (82.9) 
Missing 23 82 
   
Glycoprotein inhibitor used 378/2751 (13.7) 751/5058 (14.9) 
Missing 318 495 
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Recent fibrinolysis 30/1268 (2.4) 40/2182 (1.8) 
Missing 1801 3371 
   
Mechanical support 46/2825 (1.6) 174/5209 (3.3) 
Missing 244 344 
   
Temporary pacing 12/2819 (0.4) 42/5169 (0.8) 
Missing 250 384 
 1 
 2 
Values are mean ± SD or n/denominator (%). ACS acute coronary syndrome, MI myocardial 3 
infarction, CABG coronary artery bypass grafting, LV left ventricular, EF ejection fraction, 4 
TIA transient ischemic attack. 5 
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PCI Procedures performed in the England and Wales (Jan 2005 - Mar 2014) 
                729,268 
 
    Rotational Atherectomy Procedures 
   9,712 
                  Exclusions 1090 
   
Rotational Atherectomy Procedures analysed 
  8,622 
 
                Radial = 3,069     Femoral = 5,553 
 
 
Figure 1. Flowchart of eligibility and exclusions of the BCIS-NICOR dataset. 
 
Non-study access site used 313 
Missing access site data 435 
Missing 30-day mortality data 342 
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Figure 2. Year of procedure for radial and femoral cases (Jan 2005 to Mar 2014). 
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